Wasatch Global Investors, an asset management company, released its “Wasatch Small Cap Growth Strategy” fourth-quarter 2024 ...

Outside of the U.S., where OrganOx has a larger footprint, livers account for about 1% of TransMedics Group's sales. If ...

New York, New York-- (Newsfile Corp. - March 17, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against TransMedics Group, Inc. (NASDAQ: TMDX) ...

TransMedics Group operates an organ transplant ecosystem under which it offers patented technology to preserve and mobilize organs, services that support transplant centers and medical teams, and a ...

TransMedics' strong Q4 performance and market share growth signal a promising future for investors. Click here to find out ...

If you purchased or acquired securities in TransMedics between February 23, 2023 and January 10, 2025 and would like to ...

TransMedics Group (NASDAQ:TMDX – Get Free Report)‘s stock had its “buy” rating restated by Canaccord Genuity Group in a ...

The organ transplant technology specialist significantly exceeded Wall Street's estimates in the fourth quarter.

TransMedics Group's organ care system can preserve multiple organs, but livers are responsible for 70% of total sales. OrganOx markets a normothermic machine perfusion device approved to preserve ...

SAN FRANCISCO, March 13, 2025 (GLOBE NEWSWIRE) -- A class-action lawsuit has been filed against TransMedics Group, Inc. (NASDAQ: TMDX), a medical technology company specializing in organ ...

It's been a rough several months for TransMedics Group (NASDAQ: TMDX) shareholders. The stock has been beaten down by about 62% from the peak it set last August. The company's warm perfusion ...